rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Harnessing the Potential of Dendritic Cell-Derived Exosomes as Tools for Immunotherapy in Ovarian Cancer
  name:
    name part: Jimenez, Yajaira Sofia
    role:
      role term: creator
    role:
      role term: author.
  name:
    name part: Huston , David
    role:
      role term: thesis advisor.
  name:
    name part: Texas A&M University
    role:
      role term: degree granting institution.
  type of resource: text
  genre: bibliography
  origin info:
    place:
      place term: txu
    date issued: 2023
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: remote
    extent: 1 online resource.
  abstract: Ovarian cancer is the second most common gynecologic cancer in the United States. Part of what makes ovarian cancer so deadly is its ability to steadily grow in the peritoneum undetected until it reaches advanced stages. Therapies used to treat ovarian cancer include debulking surgery and platinum-based chemotherapy, but even after undergoing this treatment, there is a 70% remission rate. Current studies show that using dendritic cells for T cell activation can be a useful approach to prime our immune system against tumor cells in efforts to increase survival rate and decrease relapses. Although immunotherapy is a promising cancer treatment method, it fails to have an impact on patients with advanced ovarian cancer due to the immunosuppressive and heterogeneous micro-environment and impaired lymphatic drainage created by cancer cells within the peritoneal cavity. We are interested in boosting the anti-tumor immunity by employing exosomes derived from dendritic cells (DC)-based vaccines (Dex) for their capacity of overcoming the transport barriers, bypassing the immunosuppressive environment, prompting T cell infiltration in target organs, and activating them. To address this, we have specifically activated DCs and evaluate the potential of Dex to induce an anti-tumor immune response in vitro. Once adequate activation was achieved, in vivo studies using a metastatic ovarian cancer model available at Corradetti Lab (HMRI) have been used to determine biodistribution of the Dex using various injection routes. The electronic version of this dissertation is accessible from https://hdl.handle.net/1969.1/197150
  note: by Yajaira Jimenez.
  note: "Major Subject: Medical Sciences"
  note: Includes vita.
  note: Master of Science Texas A&M University 2022 https://hdl.handle.net/1969.1/197150
  note: Includes bibliographical references.
  note: Text (Thesis)
  subject:
    topic: Major Medical Sciences
  subject:
    topic: ovarian cancer
  subject:
    topic: immunotherapy
  subject:
    topic: dendritic cells
  subject:
    topic: cancer therapy
  subject:
    topic: metastatic ovarian cancer
  subject:
    topic: immunology
  identifier: https://hdl.handle.net/1969.1/197150
  record info:
    record content source: TXA
    record creation date: 240819
    record change date: 20240820145850.6
    record identifier: in00005463465
    language of cataloging:
      language term: eng